Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
Cancer Radiother
; 23(6-7): 541-558, 2019 Oct.
Article
en En
| MEDLINE
| ID: mdl-31421999
ABSTRACT
PURPOSE:
Literature review reporting results of salvage brachytherapy and stereotactic body radiotherapy for prostate recurrence only after radiotherapy for prostate cancer. MATERIALS ANDMETHODS:
A total of 38 studies (including at least 15 patients per study) were analysed 19 using low-dose-rate brachytherapy, nine high-dose-rate brachytherapy and ten stereotactic body radiotherapy. Only five studies were prospective. The median numbers of patients were 30 for low-dose-rate brachytherapy, 34 for high-dose-rate brachytherapy, and 30 for stereotactic body radiotherapy. The median follow-up were 47months for low-dose-rate brachytherapy, 36months for high-dose-rate brachytherapy and 21months for stereotactic body radiotherapy.RESULTS:
Late genitourinary toxicity rates ranged, for grade 2 from 4 to 42% for low-dose-rate brachytherapy, from 7 to 54% for high-dose-rate brachytherapy and from 3 to 20% for stereotactic body radiotherapy, and for grade 3 or above from 0 to 24% for low-dose-rate brachytherapy, from 0 to 13% for high-dose-rate brachytherapy and from 0 to 3% for grade 3 or above (except 12% in one study) for stereotactic body radiotherapy. Late gastrointestinal toxicity rates ranged, for grade 2 from 0 to 6% for low-dose-rate brachytherapy, from 0 to 14% for high-dose-rate brachytherapy and from 0 to 11% for stereotactic body radiotherapy, and for grade 3 or above from 0 to 6% for low-dose-rate brachytherapy, and from 0 to 1% for high-dose-rate brachytherapy and stereotactic body radiotherapy. The 5-year biochemical disease-free survival rates ranged from 20 to 77% for low-dose-rate brachytherapy and from 51 to 68% for high-dose-rate brachytherapy. The 2- and 3-year disease-free survival rates ranged from 40 to 82% for stereotactic body radiotherapy. Prognostic factors of biochemical recurrence have been identified.CONCLUSION:
Despite a lack of prospective data, salvage reirradiation for prostate cancer recurrence can be proposed to highly selected patients and tumours. Prospective comparative studies are needed.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Braquiterapia
/
Terapia Recuperativa
/
Radiocirugia
/
Reirradiación
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Humans
/
Male
Idioma:
En
Revista:
Cancer Radiother
Asunto de la revista:
NEOPLASIAS
/
RADIOTERAPIA
Año:
2019
Tipo del documento:
Article
País de afiliación:
Francia